Abstract
In this study, we analyzed the influence of mesenchymal stromal cells derived from lymph nodes of non-Hodgkin's lymphomas, on effector functions and differentiation of Vdelta (6)2 T lymphocytes. We show that: i) lymph-node mesenchymal stromal cells of non-Hodgkin's lymphoma inhibit NKG2D-mediated lymphoid cell killing, but not rit-uximab-induced antibody-dependent cell-mediated cytotoxicity, exerted by V62 T lymphocytes; ii) pre-treatment of mesenchymal stromal cells with the aminobisphosphonates pamidronate or zoledronate can rescue lymphoma cell killing via NKG2D; iii) this is due to inhibition of transforming growth factor-p and increase in interleukin-15 production by mesenchymal stromal cells; iv) aminobisphosphonate-treated mesenchymal stromal cells drive V62 T-lym-phocyte differentiation into effector memory T cells, expressing the Thelper1 cytokines tumor necrosis factor-a and interferon-y. In non-Hodgkin's lymphoma lymph nodes, V62 T cells were mostly naïve; upon co-culture with autologous lymph-node mesenchymal stromal cells exposed to zoledronate, the percentage of terminal differentiated effector memory V62 T lymphocytes increased. In all non-Hodgkin's lymphomas, low or undetectable transcription of Thelper1 cytokines was found. In diffused large B-cell lymphomas and in a group of follicular lymphoma, transcription of transforming growth factor p and interleukin-10 was enhanced compared to non-neoplastic lymph nodes. Thus, in non-Hodgkin lymphomas mesenchymal stromal cells interfere with V62 T-lymphocyte cytolytic function and differentiation to Thelper1 and/or effector memory cells, depending on the prominent in situ cytokine milieu. Aminobisphosphonates, acting on lymph-node mesenchymal stromal cells, can push the balance towards Thelper1/effector memory and rescue the recognition and killing of lymphoma cells through NKG2D, sparing ritux-imab-induced antibody-dependent cell-mediated cytotoxicity.
| Original language | English |
|---|---|
| Pages (from-to) | 131-139 |
| Number of pages | 9 |
| Journal | Haematologica |
| Volume | 99 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 1 2014 |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vd 2 T lymphocytes in non-hodgkin lymphomas. / Musso, Alessandra; Catellani, Silvia; Canevali, Paolo; Tavella, Sara; Venè, Roberta; Boero, Silvia; Pierri, Ivana; Gobbi, Marco; Kunkl, Annalisa; Ravetti, Jean Louis; Zocchi, Maria Raffaella; Poggi, Alessandro.
In: Haematologica, Vol. 99, No. 1, 01.01.2014, p. 131-139.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vd 2 T lymphocytes in non-hodgkin lymphomas
AU - Musso, Alessandra
AU - Catellani, Silvia
AU - Canevali, Paolo
AU - Tavella, Sara
AU - Venè, Roberta
AU - Boero, Silvia
AU - Pierri, Ivana
AU - Gobbi, Marco
AU - Kunkl, Annalisa
AU - Ravetti, Jean Louis
AU - Zocchi, Maria Raffaella
AU - Poggi, Alessandro
PY - 2014/1/1
Y1 - 2014/1/1
N2 - In this study, we analyzed the influence of mesenchymal stromal cells derived from lymph nodes of non-Hodgkin's lymphomas, on effector functions and differentiation of Vdelta (6)2 T lymphocytes. We show that: i) lymph-node mesenchymal stromal cells of non-Hodgkin's lymphoma inhibit NKG2D-mediated lymphoid cell killing, but not rit-uximab-induced antibody-dependent cell-mediated cytotoxicity, exerted by V62 T lymphocytes; ii) pre-treatment of mesenchymal stromal cells with the aminobisphosphonates pamidronate or zoledronate can rescue lymphoma cell killing via NKG2D; iii) this is due to inhibition of transforming growth factor-p and increase in interleukin-15 production by mesenchymal stromal cells; iv) aminobisphosphonate-treated mesenchymal stromal cells drive V62 T-lym-phocyte differentiation into effector memory T cells, expressing the Thelper1 cytokines tumor necrosis factor-a and interferon-y. In non-Hodgkin's lymphoma lymph nodes, V62 T cells were mostly naïve; upon co-culture with autologous lymph-node mesenchymal stromal cells exposed to zoledronate, the percentage of terminal differentiated effector memory V62 T lymphocytes increased. In all non-Hodgkin's lymphomas, low or undetectable transcription of Thelper1 cytokines was found. In diffused large B-cell lymphomas and in a group of follicular lymphoma, transcription of transforming growth factor p and interleukin-10 was enhanced compared to non-neoplastic lymph nodes. Thus, in non-Hodgkin lymphomas mesenchymal stromal cells interfere with V62 T-lymphocyte cytolytic function and differentiation to Thelper1 and/or effector memory cells, depending on the prominent in situ cytokine milieu. Aminobisphosphonates, acting on lymph-node mesenchymal stromal cells, can push the balance towards Thelper1/effector memory and rescue the recognition and killing of lymphoma cells through NKG2D, sparing ritux-imab-induced antibody-dependent cell-mediated cytotoxicity.
AB - In this study, we analyzed the influence of mesenchymal stromal cells derived from lymph nodes of non-Hodgkin's lymphomas, on effector functions and differentiation of Vdelta (6)2 T lymphocytes. We show that: i) lymph-node mesenchymal stromal cells of non-Hodgkin's lymphoma inhibit NKG2D-mediated lymphoid cell killing, but not rit-uximab-induced antibody-dependent cell-mediated cytotoxicity, exerted by V62 T lymphocytes; ii) pre-treatment of mesenchymal stromal cells with the aminobisphosphonates pamidronate or zoledronate can rescue lymphoma cell killing via NKG2D; iii) this is due to inhibition of transforming growth factor-p and increase in interleukin-15 production by mesenchymal stromal cells; iv) aminobisphosphonate-treated mesenchymal stromal cells drive V62 T-lym-phocyte differentiation into effector memory T cells, expressing the Thelper1 cytokines tumor necrosis factor-a and interferon-y. In non-Hodgkin's lymphoma lymph nodes, V62 T cells were mostly naïve; upon co-culture with autologous lymph-node mesenchymal stromal cells exposed to zoledronate, the percentage of terminal differentiated effector memory V62 T lymphocytes increased. In all non-Hodgkin's lymphomas, low or undetectable transcription of Thelper1 cytokines was found. In diffused large B-cell lymphomas and in a group of follicular lymphoma, transcription of transforming growth factor p and interleukin-10 was enhanced compared to non-neoplastic lymph nodes. Thus, in non-Hodgkin lymphomas mesenchymal stromal cells interfere with V62 T-lymphocyte cytolytic function and differentiation to Thelper1 and/or effector memory cells, depending on the prominent in situ cytokine milieu. Aminobisphosphonates, acting on lymph-node mesenchymal stromal cells, can push the balance towards Thelper1/effector memory and rescue the recognition and killing of lymphoma cells through NKG2D, sparing ritux-imab-induced antibody-dependent cell-mediated cytotoxicity.
UR - http://www.scopus.com/inward/record.url?scp=84892598990&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892598990&partnerID=8YFLogxK
U2 - 10.3324/haematol.2013.097311
DO - 10.3324/haematol.2013.097311
M3 - Article
VL - 99
SP - 131
EP - 139
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 1
ER -